Medical technology and pharma firms stepped forward today.
Woundcare specialist Tissue Regenix (LON:TRX) saw shares rise over 9% as it has reached another milestone - breaking the US$1mln mark for sales of its DermaPure product in the US.
DermaPure was given approval from the US government for its state-funded programme Medicare only last year.
The product was issued the Medicare 'Q' code for reimbursement in November which became effective as of the beginning of this year, and is now available to almost 65% of Medicare beneficiaries, across 31 states.
Sticking to the med-tech sector, Collagen Solutions (LON:COS) trimmed its revenue guidance after product orders came through more slowly than expected, but remains upbeat over prospects overall.
The group is developing a range of collagen-based medical implants such as cartilages.
Due to the delays, it now expects annual revenues to March to be around £2.8mln against market forecasts of £3.6mln previously with losses of about £750,000.
Most of the £800,000 slippage (£359,000) was down to delays in ordering and testing Collagen said, with £256,000 the result of lower than expected orders; £156,000 due to customer takeovers and a cancellation (£49,000).
Learning Technologies Group (LON:LTG) today gave an upbeat assessment of prospects as it said it was trading in line with expectations.
Profit margins and cash generation remained strong, LTG said, with the company sitting with £7mln on the balance sheet, up from £4.4mln a year ago.
The company, which is at the vanguard of electronic learning, is seeing the benefit from its July acquisition Eukleia Training.
Shares were unchanged at 27.75p.
Redx Pharma’s (LON:REDX) reported a final results statement, which charted a significant period of progress for the drug research firm.
It achieved in ‘proof of concept’ in a further two programs and took three drug candidates into formal pre-clinical development.
Its oncology pipeline includes a programme for skin and blood cancers as well as auto-immune diseases.
Among the landmarks of the 12 months to September 30 was the launch of immunology research division and a tie up with fellow AIM-listee Horizon Discovery.
As is common with companies at this formative stage of development, Redx was loss-making - of £8.2mln.
Finally, shares in Kromek (LON:KMK) went over 3% higher on Wednesday after a long standing customer renewed a contract for detector modules worth US$957,000.
Kromek, the imaging technology group, said they will be incorporated into the unnamed customer's bone mineral densitometry (BMD) diagnostics systems used to analyse the health of bones, allowing clinicians to accurately detect Osteoporosis.
The new contract will be delivered over a 20-month period.